GINS3 and colorectal carcinoma: As previously reported, KRAS mutations are widespread in CRC (Raskov et al., 2020), but to a lesser extent in GINS3 (12%) (Figure 9A and Figure 9—figure supplement 1A), in line with its inferior activity of KRAS signaling detected in the discovery cohort.